Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Phase 2 Recruiting
131 enrolled
MAIA-ovarian
Phase 1/2 Recruiting
60 enrolled
Hydrochloric Acid Lock Therapy for Central Line-associated Bloodstream Infections
Phase NA Recruiting
250 enrolled
Regional Anesthesia in Minimally Invasive Lumbar Spine Surgery
Phase 4 Recruiting
125 enrolled
AIVAA
Phase 2 Recruiting
90 enrolled
DEXDES Trial: Dexmedetomidine-Desflurane Combination in Laparoscopic Colectomy
Phase NA Recruiting
40 enrolled
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Phase 3 Recruiting
386 enrolled
LOLIPOP
Phase 3 Recruiting
4,300 enrolled
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Phase 3 Recruiting
274 enrolled
Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma
Phase 1 Recruiting
56 enrolled
MAGIC-AKI
Phase 2 Recruiting
130 enrolled
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
Phase 2 Recruiting
40 enrolled
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Phase 3 Recruiting
60 enrolled
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Phase 2 Recruiting
51 enrolled
A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study
Phase 1 Recruiting
18 enrolled
Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery
Phase NA Recruiting
1,988 enrolled
Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery
Phase NA Recruiting
4,532 enrolled
Analgesic Efficacy of Maxigesic in Breast Cancer Surgery
Phase NA Recruiting
84 enrolled
DEXFLAP
Phase NA Recruiting
60 enrolled
Pre Operative Trastuzumab in Operable Breast Cancer
Phase 3 Recruiting
1,100 enrolled